VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
2.820
+0.090 (3.30%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions.

The company’s lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.

It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications.

The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020.

VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

VYNE Therapeutics Inc.
VYNE Therapeutics logo
Country United States
Founded 2003
IPO Date Jan 25, 2018
Industry Biotechnology
Sector Healthcare
Employees 10
CEO David Domzalski

Contact Details

Address:
685 Route 202/206 N, Suite 301
Bridgewater, New Jersey 08807
United States
Phone 800 775 7936
Website vynetherapeutics.com

Stock Details

Ticker Symbol VYNE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001566044
CUSIP Number 92941V209
ISIN Number US92941V3087
Employer ID 45-3757789
SIC Code 2834

Key Executives

Name Position
David T. Domzalski Chief Executive Officer, President and Director
Dr. Iain A. Stuart Ph.D. Chief Scientific Officer
Mutya Harsch J.D. General Counsel, Chief Legal Officer and Company Secretary
Dr. Subhashis Banerjee M.D. Senior Vice President of Clinical Development
Dr. Darrell S. Rigel FAAD, M.D. Consultant

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 ARS Filing
Nov 12, 2024 DEF 14A Other definitive proxy statements
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Sep 12, 2024 8-K Current Report
Aug 14, 2024 10-Q Quarterly Report
Aug 14, 2024 8-K Current Report
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report